LNCARSR and renal carcinoma: For example, Qu et al demonstrated that high expression of lncARSR promotes renal cancer resistance to sunitinib by competitively binding Mir‐34 and Mir‐449 and activating the STAT3/AKT/ERK signaling pathway.58